Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor

Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor artwork

S3E10: Talking to Patients About Cannabis: A PMHNP Script

Nov 18, 202620 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! A no-judgment script for asking about cannabis, explaining potency and psychosis risk, and answering "it's my medicine" with real numbers. Built for new PMHNPs. In this Deep Dive episode, two hosts walk through “Talking to Patients About Cannabis: A PMHNP Script” from the Psych NP Fellowship blog by Lindsay Hill, DNP, PMHNP-BC. Key takeaways: • “Do you use marijuana?” gets a yes or no. The questions that change care are how often, what product, how strong, since what age, and what it does for the patient. • Daily use of high-potency cannabis (above 10% THC) was tied to about 4.8 times the odds of a psychotic disorder in the 2019 EU-GEI study. • Danish registry data suggest up to 30% of schizophrenia cases in men ages 21 to 30 might have been prevented by averting cannabis use disorder. • The CDC estimates about 3 in 10 people who use cannabis have cannabis use disorder, with higher risk for those who start young or use often. • When a patient says “it’s my medicine,” the move is curiosity, not a debate: name what it helps, name what it may be making worse, and agree on one small experiment. • Success is a measurable change, such as fewer days, lower potency, or no use before bed, plus a patient who keeps telling the truth at the next visit. Read the full article: https://psychnpfellowship.com/talking-to-patients-about-cannabis-pmhnp-confidence-script-2026/ Explore the Psych NP Fellowship: https://psychnpfellowship.com/pmhnp-fellowship/ This content is for educational purposes and does not replace individualized clinical judgment or supervision.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

You know, usually when we talk about a medical intake, there's this expectation of just absolute precision. Right. Like it's all very clinical and neat. Exactly. You go to a clinic, they check your blood pressure, they ask if you smoke, and it's all just very binary, yes or no. But today, we're looking at this massive problem in modern psychiatry. I mean, we're talking about why the simple question, you know, do you use marijuana is just entirely obsolete. It really is, yeah. It's a completely broken system. The landscape

of legalization and, well, product potency has just completely outpaced the way we screen for risk in a clinical setting. Yeah, 100%. OK, so let's unpack this. Today, we are taking a deep dive into a highly practical step -by -step masterclass on how clinicians, specifically new and early career psychiatric nurse practitioners, PMHNPs, should actually be talking to you, the patient, about cannabis. Right. We're using this fantastic clinical guide from the Psych NP Fellowship.

It's authored by Lindsay Hill. And we're sort of blending that with deep background data from the CDC, the National Institute on Drug Abuse, and Psychiatric Times, just to, you know, look at the hard science behind Lindsay's guidelines. Which is so crucial because if you just ask a patient, you know, do you use cannabis? Getting a yes tells you almost nothing. Almost nothing. Yeah, I mean, asking a simple yes or no question about cannabis today is as clinically useless as asking a patient, do you drink liquids when

you're trying to figure out if they have alcohol use disorder? Right. It tells you that they ingest something, sure, but it gives you absolutely zero data on their actual risk profile or the volume or the biological impact on their brain. Do you drink liquids? I love that analogy. It's like asking someone, do you eat food? Exactly. Think about it. You could have one patient who takes like two tiny puffs of a really low THC joint twice a year at a summer concert. Yeah. And then you have another patient who's vaping

a 45 % THC concentrate from the exact moment they wake up to the moment they go to bed. Right. And they both check the exact same yes box on the intake form, but their clinical risk profiles are just universes apart. Universes apart. And if a provider stops at the check box, they're essentially flying blind. Yeah. which is why the Psych NP Fellowship article really emphasizes throwing out the checkbox completely and gathering five very specific details. Okay, so let's get into those. Right. So the first one is frequency.

Not just do you use, but how many days per week? And on those days, how many times a day? Right, because there's obviously a massive biological difference between, you know, casual weekend use and waking and baking every single morning. Exactly. And that leads right into the second detail, which is the product or the form. We're talking about traditional flour versus vape cartridges or concentrates or edibles. And this is actually where the CDC background data really shocked me. Oh, the potency increase? Yeah. They noted

that the average THC concentration in research samples almost doubled in just a decade. It went from like 9 % in 2008 to 17 % in 2017. And that's just the average. I mean, the CDC points out that products available in some legal dispensaries average around 22 % THC, with some extracts hitting an incredible 45 % or even higher. Which is just wild. It is. When we talk about products like wax or shatter or butane hash oil, I mean, these are highly refined concentrates. They deliver

this massive, immediate payload of THC that crosses the blood -brain barrier almost instantly. This is emphatically not the traditional flower most adults remember from the 1980s or 90s. Right, which means you can't just ask what they're using, you have to ask how strong it is. So that's the third detail, potency. What does the label actually say? Because of legal retail labeling, a lot of patients actually know their THC percentages now. Precisely, they can tell you. And then the fourth detail is age at first regular use. This

is so critical for psychiatric providers, because the human brain is under intense construction during adolescence. The endocannabinoid system plays a huge role in how the brain wires itself. So early and heavy exposure to high THC products disrupts that neuroplasticity. It carries significantly more long -term risk for the developing brain compared to someone who, say, starts using in their late 20s. That makes total sense. I mean, if the house is still being built, throwing a massive chemical wrench into the construction process is going to leave structural damage.

Exactly. And finally, the fifth detail Lindsay points out is function. What is the patient actually using it for? Are they trying to fix their sleep? Numbing anxiety? Are they just bored? Right. Is it a social habit or is it something they literally can no longer skip without feeling physically ill? Right, because why they use it tells you what you actually need to treat. And while gathering these five details, the guidelines flag two major clinical warning signs. Which are? Any personal or family history of psychosis

or bipolar disorder and any sign that the patient cannot cut back when they genuinely want to. Okay, so once a provider has this full picture, you know, frequency, product, potency, age and function, they really need the scientific literacy to understand what that data actually means. Yes. And this is where things get kind of heavy. The article highlights three key statistics that psychiatric nurse practitioners must, as Lindsay says, know cold. The first one is from the EUGEI study, which is a massive, multi -centric study

across Europe and Brazil. They found that daily cannabis use carried about 3 .2 times the odds of developing a psychotic disorder. And it gets even more intense than that. When that study looked at daily use of high -potency cannabis, which they defined as anything above 10 % THC, the odds of a psychotic disorder jumped to 4 .8 times. Wow. Yeah. They estimated that 12 .2 % of all new psychosis cases across their study sites could be directly linked to high -potency use. Okay, here's where it gets really interesting

to me because... It's one thing to hear 4 .8 times the odds, right? But what is actually happening in the brain? Like, why does high -potency THC trigger psychosis? Well, what's fascinating here is the biology of the dopamine system. THC binds to CB1 receptors in the brain. In high doses, this triggers a massive cascade of dopamine, particularly in an area of the brain called the striatum. OK. Now, dopamine is often called the reward chemical, but it's really the salience chemical. It tells your brain what's important, what to pay attention to. So if you flood the

brain with dopamine? Exactly. If you flood it with an artificial surge of dopamine, the brain starts attaching intense significance to completely random mundane things. A shadow in the corner suddenly feels incredibly threatening. Oh, wow. Yeah. Or a passing comment from a friend feels like a deep conspiracy. That hyper salience is the biological foundation of paranoia and psychosis. And the higher the THC payload, the harder you're hitting that dopamine system. OK, that perfectly explains the mechanism. And that 10 % threshold

for high potency in the study is honestly terrifying when you remember we just talked about legal vapes hitting 45 % today. Right. So moving to the second stat you need to know, Cold, it focuses on young men drawn from NIDA -supported research using Danish registry data. And they track nearly 7 million people over five decades. Which is a remarkably robust study. They looked at the link between cannabis use disorder and schizophrenia and found the association was strongest in young men. Their models estimated that as many as 30

% of schizophrenia cases in men ages 21 to 30 might have been prevented by averting cannabis use disorder. Up to 30%. That is just a staggering public health implication. It really is. And the third stat is about dependence straight from the CDC. They estimate that approximately 3 in 10 people who use cannabis have cannabis use disorder or CUD. But, and here is the crucial caveat that Lindsay's article emphasizes, these studies are observational. Right. They show a very strong dose -response link, meaning the

more you use and the stronger it is, the higher the risk. But they do not prove that cannabis is the singular cause of psychosis in a vacuum. It interacts with genetics and environment. Providers must state this clearly. You have to say, you know, most people who use cannabis will never develop psychosis. If you oversell the risk or frame it as a guaranteed outcome, you instantly lose the patient's trust. Which brings up a really tough dynamic. I mean, if I'm a clinician or honestly, even just a friend or a parent trying

to talk to someone about their use, how do I drop a terrifying stat like 4 .8 times the odds of psychosis without sounding like some fear -mongering 1980s school assembly. Right, the old, this is your brain on drugs routine. Exactly. Because my instinct is that if you just throw those numbers at someone, they're going to put up a wall immediately. And that is exactly the hurdle the clinical script is designed to clear. You cannot just launch into a lecture. The execution is just as important as the data. The protocol here is to be curious first and specific second.

Okay, so let's walk through the actual words the guide suggests. First, you have to normalize the conversation. The suggested opening line is brilliant. You just say, a lot of my patients use cannabis and it can affect sleep, mood, anxiety. No judgment here. I just want the real picture. It disarms the patient immediately. It disarms it. Think about it from the patient's perspective, right? You're sitting in a very vulnerable position. That phrasing basically says, I'm not here to arrest you or judge your morality. I'm here to do my job as a medical professional who understands how the body works. Yeah. And right alongside

that normalization is the absolute necessity of a neutral face. Oh, man. Yeah. Imagine you're the patient and you bravely admit that you vape high potency concentrates every single morning and the provider literally gasps or raises their eyebrows. You learn a lesson very quickly. You learn to lie. Exactly. Give smaller numbers next time. Totally. Total poker face is required. Once you've normalized it, and gather the data neutrally, the next step is crucial. You ask permission. You say, would it be OK if I shared

what we know about strong cannabis and mental health? That's classic motivational interviewing, right? Yes, exactly. By asking permission, you keep the patient in the driver's seat. You aren't lecturing at them. You're offering information for them to consider. And if they say yes, you target the data. You don't just dump all three of those terrifying stats on them at once. You pick the one that matters to their specific life. Right. If you have a young male patient with a family history of schizophrenia, you share the Danish registry stat. If you have a patient with panic disorder who vapes daily, you share

the CDC stat about the 3 in 10 risk of dependence. And then you end with the simple question, what do you make of that? Ending with what do you make of that is so powerful. It forces the patient to synthesize the information and apply it to their own life. It invites them into a partnership. It reminds me of the difference between being a good detective versus being a bad cop. Oh, that's a good way to put it. Right? Like, patients can tell in 10 seconds if you're asking questions to understand them or asking questions to catch them doing something wrong. If you act like a

cop, they clam up to protect themselves. But if you act like a curious investigator, partnering with them to figure out their health, they give you the truth. And as Lindsay's article points out, the truth is the only thing you can actually treat. That is a perfect analogy. The truth is the foundation. But let's be realistic here. Even with the most empathetic, scientifically grounded script, providers are still going to face resistance. Oh, absolutely. I mean, let's talk about the scenario every new PMHNP dreads.

The patient leans back, crosses their arms, and defends their use by saying, you know, it's my medicine. This is the only thing that helps my anxiety, or this is the only way I can sleep. Right. If I'm sitting there, my instinct would be to pull out the charts and argue the science. But I'm guessing telling a patient you're wrong is a terrible clinical move. It is a guaranteed way to end the therapeutic relationship right then and there. The primary rule here is do not argue. do not get into a semantic debate about whether it's medicine or not. OK, so what do

you do? Instead, you validate them. You acknowledge that the short -term relief they're feeling, that immediate drop in anxiety or that ability to fall asleep, is very real to them. Because biologically, it is real in the short term. But then you explain the rebound effect. Right, the brain adaptation. How exactly does that work? Why does the anxiety come back worse? Well, if we connect this to the bigger picture of neurobiology, It comes down to receptor downregulation. OK. The human body naturally produces its own cannabinoids,

endocannabinoids, to regulate mood and sleep. When you smoke or vape, you're flooding the brain with exogenous cannabinoids. The brain is highly efficient. It senses this massive flood and says, whoa, we have way too much stimulation here. I'm going to prune back my own receptors to balance things out. So the brain literally removes its own biological hardware for coming down. Exactly. It down -regulates the receptors. So when the cannabis inevitably wears off, the brain is caught chemically in debt. It doesn't have enough receptors

to handle normal baseline stress. As a result, the patient's anxiety or insomnia spikes dramatically. This is the rebound effect. And the tragedy is the patient feels this massive spike in anxiety and interprets it as proof that they desperately need the cannabis. In reality, they are experiencing withdrawal from the very substance causing the spike. That is a massive light bulb moment. Which is why the guidelines emphasize naming the withdrawal symptoms ahead of time. You have to tell them, hey, if you stop or cut back, you might feel

irritability, low mood, poor appetite, and have some really vivid dreams or trouble sleeping that can last for weeks. Yes. By warning them, you change their framework for understanding their own bodily sensations. If they try to cut back and suddenly feel awful, they'll think, my provider told me this was the receptor downregulation repairing itself, rather than, see, I'm broken without my medicine. So once you've explained the biology, what's the actual intervention? Because you still can't just demand they quit cold turkey. No, absolutely not. You introduce

the concept of the one small experiment. You ask for one highly specific test. I love this because it's so actionable. You ask them to try lowering the THC percentage for just two weeks or, you know, try skipping morning use before work or commit to no use within two hours of bedtime. And you have them track a specific symptom score, like their anxiety from zero to 10, and you check the data together at the next visit. But here is the critical piece. If you ask them to run this experiment, you have to offer a real

alternative. Right. If a patient is using cannabis for sleep, and you ask them to stop using it before bed, you can't just leave them hanging. You have to offer an evidence -based alternative. Like what, specifically? Like cognitive behavioral therapy for insomnia, or CBT -I. This isn't just talking about sleep. It's a structured program of sleep restriction and stimulus control that actually rewires the brain's sleep drive. Or, if appropriate, a medication like an orexin antagonist. Let's clarify that real quick. What is an orexin

antagonist? So orexin is a neuropeptide in the brain that promotes wakefulness. Traditional sleeping pills like benzodiazepines work by depressing the entire central nervous system, basically sedating you. An orexin antagonist works differently. It specifically blocks the brain's stay awake signals. It targets the mechanism of insomnia without the heavy full body sedation or the same risk of dependency. If you don't offer a viable alternative like that, The experiment feels like a trap. It feels like you're just taking away

their only coping mechanism. So what does this all mean for the end goal? If we aren't demanding immediate abstinence and we're just asking for these small experiments, what actually defines a successful visit? That leads to Lindsay's section on what most people get wrong. We have to completely redefine success in modern psychiatric care regarding cannabis. The outdated goal was immediate abstinence. But measured that way, most of these conversations fail. and providers get discouraged and just stop bringing it up altogether. The new definition

of success is a measurable change like switching from high -potency concentrates to a lower THC flower or cutting out morning use. Plus, a patient who continues to tell the truth at the next visit. That continued honesty is the victory. It's fundamentally a harm reduction model. A patient who stops vaping before work has protected their livelihood. A patient cutting their THC exposure in half has protected their dopamine system. Both of those are massive clinical wins. It's like handing the patient the steering wheel while you read

the map. Even if you aren't a clinician, if you've ever tried to break a habit, you know that you're much less likely to panic and jump out of a moving car if you feel like you're in control of the speed. That's exactly it. The article also highlights another major thing people get wrong, which is the legal equal safe fallacy. Oh, yeah. Just because cannabis is legal in a state or just because a patient has a medical card does not mean a medical professional has actually weighed their psychiatric risks. This is so important for people to understand. The people working

the counter at a retail dispensary selling 45 % THC concentrates are not screening buyers for a family history of bipolar disorder or schizophrenia. No, they're not. They're retail employees, not psychiatric providers. Exactly. The assumption that the state's legal stamp of approval equals medical safety is incredibly dangerous for vulnerable brains. And then finally, there is the danger of silence. When a provider skips this conversation just because it feels awkward or they don't know the exact words to use, the patient reads that

silence as clinical approval. Wow. Yeah. Silence reads as approval. If the psychiatric professional doesn't mention the vape pen, the patient assumes it must be totally fine. That is a heavy responsibility. So the guidelines leave providers with a very specific next step. Before tomorrow's first visit, add these five words to your intake template. Frequency, product, potency, age, function. And practice that normalizing opening line out loud so you're ready. It takes the pressure off. You

don't need to have a debate. You just need to ask those five questions, share one honest biological fact, and offer one small experiment. If we synthesize everything we've looked at today, the core takeaway is clear. Legal normalization does not equal psychiatric neutrality. We have to be precise, we have to be curious, and we have to be collaborative. It changes the entire paradigm from moral judgment to precise medical inquiry. It really does. And this raises an important question, something for you to really chew on after we wrap up here.

No. As cannabis potency continues to skyrocket, and public perception of its harm continues to drop. What if we stopped viewing these intake conversations merely as substance use screening? What if we started viewing them as our most accurate diagnostic window into whole generations untreated anxiety and insomnia? Oh, wow. Because if the patient's self -medication with high -potency THC is actually down -regulating their receptors and causing the very rebound symptoms they are

desperately trying to cure, then the most radical clinical intervention you could offer them might just be genuine curiosity. What an incredible perspective shift. Genuine curiosity as the ultimate clinical intervention. Well, thank you for joining us on this deep dive. Remember to keep questioning the checkboxes. Keep learning and stay curious. We'll catch you next time.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. S3E11: Alcohol Use Disorder Medications: A PMHNP Protocol

    Nov 19, 202627 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Only 2% of adults with alcohol use disorder get medication for it. A PMHNP protocol for naltrexone, acamprosate,...

    Credit the people on this episode

  2. S3E9: Medicare 2027 Final Rule: What Changed for PMHNPs

    Nov 15, 202621 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! CMS finalized the 2027 Medicare fee schedule on November 4. See the deeper pay cut, the new 16% E/M modifier, and...

    Credit the people on this episode

  3. S3E8: PMHNP Sliding Scale Fees: A Private Practice Playbook

    Nov 13, 202618 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! A sliding scale can widen access or invite a payer audit. How PMHNPs build a written, income-based fee policy...

    Credit the people on this episode

  4. S3E7: Duty to Warn: A PMHNP Confidence Script

    Nov 11, 202623 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! A patient names someone they want to hurt. Here is how PMHNPs check state duty-to-warn law, size up the threat,...

    Credit the people on this episode

  5. S3E6: Precepting PMHNP Students: What It Pays You Back

    Nov 10, 202622 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Precepting PMHNP students can earn state tax credits of up to $10,000 a year and fill an ANCC renewal category....

    Credit the people on this episode